Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amarin
Amarin granted patent in the United States for Miraxion in Huntington disease
November 7th, 2006
Amarin Corp. plc (AMRN) announced that the United States Patent and Trademark Office has granted approval for its patent application covering the use of its proprietary ultra-pure ethyl-EPA compound (Miraxion) in Huntington disease. The patent, number 7,119,118, will run to 2021. Rick Stewart, CEO, commented, "We believe this patent substantially enhances Miraxion's already significant commercial potential. Amarin has additional patents granted for Miraxion in other central nervous system disorders, such as depression, and has many patents pending for a range of indications. We are committed to further strengthening our existing intellectual property...
Source: Drug Law Weekly (2006-11-07)
|
